Algert Global LLC trimmed its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 27.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 205,497 shares of the company's stock after selling 78,424 shares during the quarter. Algert Global LLC owned approximately 0.11% of BridgeBio Pharma worth $15,305,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently modified their holdings of the company. First Bank & Trust lifted its holdings in BridgeBio Pharma by 1.6% during the second quarter. First Bank & Trust now owns 8,797 shares of the company's stock valued at $655,000 after purchasing an additional 142 shares during the last quarter. GAMMA Investing LLC boosted its position in BridgeBio Pharma by 13.8% during the second quarter. GAMMA Investing LLC now owns 1,646 shares of the company's stock worth $123,000 after purchasing an additional 199 shares during the period. Commonwealth Equity Services LLC increased its stake in shares of BridgeBio Pharma by 4.9% in the fourth quarter. Commonwealth Equity Services LLC now owns 5,179 shares of the company's stock worth $396,000 after purchasing an additional 244 shares in the last quarter. Farther Finance Advisors LLC increased its stake in shares of BridgeBio Pharma by 91.4% in the fourth quarter. Farther Finance Advisors LLC now owns 513 shares of the company's stock worth $39,000 after purchasing an additional 245 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D raised its position in shares of BridgeBio Pharma by 0.5% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 51,896 shares of the company's stock valued at $3,970,000 after purchasing an additional 246 shares during the period. 99.85% of the stock is owned by institutional investors.
Insider Buying and Selling
In other BridgeBio Pharma news, Director Hannah Valantine sold 2,808 shares of the business's stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $68.00, for a total value of $190,944.00. Following the completion of the sale, the director owned 11,455 shares in the company, valued at approximately $778,940. The trade was a 19.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Andrea Ellis sold 17,167 shares of the stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $84.00, for a total value of $1,442,028.00. Following the sale, the director directly owned 22,579 shares of the company's stock, valued at approximately $1,896,636. This trade represents a 43.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 387,343 shares of company stock valued at $30,289,400 over the last three months. 14.23% of the stock is owned by corporate insiders.
BridgeBio Pharma Price Performance
Shares of NASDAQ:BBIO opened at $80.40 on Wednesday. The company's fifty day moving average price is $79.38 and its 200-day moving average price is $73.34. The firm has a market capitalization of $15.72 billion, a price-to-earnings ratio of -22.52 and a beta of 0.96. BridgeBio Pharma, Inc. has a one year low of $47.26 and a one year high of $93.42.
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.20). The firm had revenue of $243.68 million during the quarter, compared to analysts' expectations of $220.91 million. During the same period in the prior year, the firm earned ($0.95) EPS. The company's quarterly revenue was up 120.4% on a year-over-year basis. As a group, equities research analysts expect that BridgeBio Pharma, Inc. will post -2.62 EPS for the current year.
Wall Street Analyst Weigh In
Several brokerages have recently weighed in on BBIO. Weiss Ratings cut BridgeBio Pharma from a "sell (d)" rating to a "sell (d-)" rating in a research report on Tuesday, August 11th. Raymond James Financial cut BridgeBio Pharma from an "outperform" rating to a "market perform" rating in a report on Tuesday, May 26th. Wells Fargo & Company raised their target price on BridgeBio Pharma from $98.00 to $102.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 11th. Mizuho reduced their target price on BridgeBio Pharma from $106.00 to $96.00 and set an "outperform" rating for the company in a report on Tuesday, June 16th. Finally, Citigroup upped their price target on BridgeBio Pharma from $82.00 to $93.00 and gave the company a "neutral" rating in a research report on Thursday, July 16th. Twenty investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $100.79.
Check Out Our Latest Stock Report on BBIO
BridgeBio Pharma Company Profile
(
Free Report)
BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.
BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider BridgeBio Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BridgeBio Pharma wasn't on the list.
While BridgeBio Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
